Sign up Australia
Proactive Investors - Run By Investors For Investors

Antisense Therapeutics Limited in ASX trading halt

Antisense Therapeutics Limited in ASX trading halt

Antisense Therapeutics Limited (ASX:ANP) is preparing to outline details in relation to the ATL1103 program for multiple sclerosis.

Antisense has been granted a trading halt to prepare, with its shares placed in pre-open.

The halt will remain in place until the opening of trade on Wednesday 9th March 2016, or earlier if an announcement is made to the market.


Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

View full ANP profile

Antisense Therapeutics Timeline

Related Articles

Blood test
September 28 2016
The group has ambitions to strengthen its transatlantic focus through organic and strategic growth
A graphic of a tumour growing in the body
July 07 2016
Nanobiotix is a late clinical-stage nanomedicine company researching novel approaches to enhance radiotherapy for the local treatment of cancer.
July 26 2016
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”

© Proactive Investors 2016

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.